“This study shows that daratumumab added to KRd is a new standard of care for those patients who had previously been candidates for just KRd,” said C. Ola Landgren, M.D., Ph.D., director of the ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

The study evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI ® plus DARZALEX FASPRO ® versus DARZALEX FASPRO ® and dexamethasone with either pomalidomide or ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...

Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated 20,030 new male cases diagnosed in 2025. Multiple myeloma is the ...

Darzalex Faspro is approved for high-risk smoldering multiple myeloma, showing significant efficacy in delaying disease progression. The AQUILA trial demonstrated a 51% reduction in the risk of ...

Newly diagnosed multiple myeloma patients at Sylvester and other cancer centers are already routinely receiving the four-drug DKRd combination. "It has definitely changed my practice," said Sylvester ...

ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that ...